Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID [0.03%]
硼替佐米环磷酰胺地塞米松与利妥昔单抗治疗PGNIMD患者的对比研究
Xin Zhang,Xiao-Juan Yu,Zi Wang et al.
Xin Zhang et al.
Background: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare renal disorder for which prospective controlled treatment evidence is limited. Clone-directed therapies targeting pla...
Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies [0.03%]
自身免疫性肾小球肾炎和足细胞病中抗利妥昔单抗抗体的流行率
Jan Miroslav Hartinger,Martin Šíma,Zdenka Hrušková et al.
Jan Miroslav Hartinger et al.
Anti-drug antibody (ADA) formation against rituximab (RTX) may affect treatment efficacy, safety, and B-cell depletion kinetics, yet data across different immune-mediated diseases remain limited. We evaluated ADA formation in 1312 blood sam...
Kianoush B Kashani,Lizemarie Wium,Marlies Ostermann et al.
Kianoush B Kashani et al.
Pregnancy-associated acute kidney injury (PrAKI) remains a major contributor to maternal and fetal morbidity worldwide, with an estimated incidence of 40-100 per 10 000 pregnancies. PrAKI is substantially more prevalent in low- and middle-i...
Risk of CKD in biopsy-proven metabolic dysfunction-associated steatotic liver disease [0.03%]
代谢功能异常相关性肝脂肪变病的肾脏损害风险:一项组织学确诊研究
Fahim Ebrahimi,Christian Eichhorn,Tracey G Simon et al.
Fahim Ebrahimi et al.
Background and hypothesis: There is scarce long-term data on the risk of chronic kidney disease (CKD) in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD). We hypothesize that th...
Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID -Dexamethasone versus Rituximab in PGNMID [0.03%]
硼替佐米-环磷酰胺地塞米松与利妥昔单抗在PGLNMID中的治疗效果对比研究
Xin Zhang,Xiao-Juan Yu,Zi Wang et al.
Xin Zhang et al.
Background: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare renal disorder for which prospective controlled treatment evidence is limited. Clone-directed therapies targeting pla...
Difelikefalin-associated adverse drug event signals: a real-world pharmacovigilance study from the FAERS database [0.03%]
基于FAERS数据库的迪拉非兰相关不良事件信号的药物警戒研究
Jinshan Zhao,Quanyu Qiu,Jidong Zhang et al.
Jinshan Zhao et al.
Background and objective: Difelikefalin, a peripherally acting selective κ-opioid receptor agonist, is approved for treating chronic kidney disease-associated pruritus (CKD-aP) in adults on hemodialysis. However, real-wo...
Becky Mingyao Ma,Shirley Pik Ying Hue,Wei Ma et al.
Becky Mingyao Ma et al.
Background: A significant proportion of patients present with chronic kidney disease of unexplained cause (CKDx) despite standard-of-care diagnostic workup. Data from Australian, European and United States cohorts show th...
Sex disparities in receiving evidence-based medications in patients with CKD [0.03%]
慢性肾脏病患者接受循证药物治疗的性别差异
Rui Du,Hannah Wallace,Jeffrey T Ha et al.
Rui Du et al.
Background and hypothesis: Chronic kidney disease (CKD) is a growing global health burden. While studies have demonstrated sex disparities in CKD prevalence and outcomes, evidence on sex-based differences in therapeutic m...
Klotho suppresses cyst growth in ADPKD through the regulation of ferroptosis and reversing DNA methylation [0.03%]
克洛托通过调节铁死亡和逆转DNA甲基化抑制ADPKD囊肿生长
Jiayi Lv,Cheng Xue,Linda Xiaoyan Li et al.
Jiayi Lv et al.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth, inflammation, fibrosis, and renal failure. Klotho is a renoprotective protein with anti-proliferative, anti-inf...